The US Department of Justice is supporting AbbVie in its efforts to overturn the Colorado law governing the 340B drug rebate program.[1] This Colorado law prohibits pharmaceutical companies from restricting the 340B drug rebate program.[1] The law removes AbbVie's ability to set conditions on offers in the 340B program.[1] It forces AbbVie to sell more drugs at deep discounts.[1] AbbVie defends its challenge to Colorado's drug discount law.[1]